The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2022
Filed:
Apr. 30, 2019
Applicant:
The Trustees of Indiana Univerity, Bloomington, IN (US);
Inventors:
Jaipal Singh, Carmel, IN (US);
Kerry Fowler, Seattle, WA (US);
Assignee:
The Trustees of Indiana University, Bloomington, IN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 65/19 (2006.01); C07C 65/24 (2006.01); C07C 65/17 (2006.01); C07C 233/81 (2006.01); C07D 257/04 (2006.01); C07C 317/32 (2006.01); C07C 211/55 (2006.01); C07C 323/62 (2006.01); C07C 215/74 (2006.01); C07C 65/40 (2006.01); C07C 49/513 (2006.01); C07C 63/64 (2006.01); C07D 209/18 (2006.01); C07D 263/32 (2006.01); C07D 213/55 (2006.01); C07C 65/10 (2006.01); C07D 295/16 (2006.01); C07D 277/30 (2006.01); C07D 333/24 (2006.01); C07C 233/65 (2006.01);
U.S. Cl.
CPC ...
C07C 65/19 (2013.01); C07C 49/513 (2013.01); C07C 63/64 (2013.01); C07C 65/10 (2013.01); C07C 65/17 (2013.01); C07C 65/24 (2013.01); C07C 65/40 (2013.01); C07C 211/55 (2013.01); C07C 215/74 (2013.01); C07C 233/65 (2013.01); C07C 233/81 (2013.01); C07C 317/32 (2013.01); C07C 323/62 (2013.01); C07D 209/18 (2013.01); C07D 213/55 (2013.01); C07D 257/04 (2013.01); C07D 263/32 (2013.01); C07D 277/30 (2013.01); C07D 295/16 (2013.01); C07D 333/24 (2013.01); C07C 2601/16 (2017.05); C07C 2602/08 (2017.05);
Abstract
Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.